{"entity":{"id":"bavarian-nordic","kind":"company","name":"Bavarian Nordic","aka":["Bavarian Nordic A/S"],"tldr":"Bavarian Nordic is a Danish vaccine company whose poxvirus-based prostate cancer vaccine PROSTVAC failed the phase 3 PROSPECT trial in 2017, after which it concentrated on infectious disease vaccines such as its smallpox and mpox vaccine.","summary":"Bavarian Nordic, based in Hellerup near Copenhagen and listed on Nasdaq Copenhagen, built its business on the modified vaccinia Ankara platform. In cancer it developed PROSTVAC (rilimogene galvacirepvec), a vaccinia and fowlpox vaccine against prostate-specific antigen, which did not improve survival in the phase 3 PROSPECT trial in metastatic castration-resistant prostate cancer reported in 2017, and CV301, a vaccine against CEA and MUC1 tested with checkpoint inhibitors. The company now focuses on travel and public health vaccines. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Bavarian_Nordic","links":[{"label":"Official website","url":"https://www.bavarian-nordic.com"},{"label":"ClinicalTrials.gov: trials led by Bavarian Nordic","url":"https://clinicaltrials.gov/search?lead=Bavarian%20Nordic"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Bavarian_Nordic"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["prostate"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Hellerup","country":"DK","companyType":"biotech","website":"https://www.bavarian-nordic.com","stage":"public","investors":[],"funding":[]},"route":"/companies/bavarian-nordic/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"shared-antigen-vaccine","kind":"technology","name":"Off-the-shelf cancer vaccines","route":"/technologies/shared-antigen-vaccine/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"drug":[{"id":"prostvac","kind":"drug","name":"PROSTVAC","route":"/drugs/prostvac/"}],"trial":[{"id":"prospect-prostvac","kind":"trial","name":"PROSPECT","route":"/trials/prospect-prostvac/"}]}}